48 results on '"Mourey L"'
Search Results
2. Caractéristiques, tolérance et efficacité des patients âgés de plus ou moins 75 ans traités par [177Lu]Lu-PSMA-617 en France dans le cadre de l’accès précoce
3. 1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
4. KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)
5. Can Massive Open Online Course (MOOC) be used to raise awareness in geriatric oncology among healthcare professionals? A French experience
6. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC)
7. 670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
8. Résultats oncologiques des patients ayant des ganglions lymphatiques positifs au moment de la cystectomie radicale avec ou sans chimiothérapie néoadjuvante
9. 722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study
10. 625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
11. 620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
12. KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
13. KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
14. ORGANIZATION OF CLINICAL RESEARCH IN GERIATRIC ONCOLOGY IN FRANCE
15. Lymphadénectomie rétropéritonéale robot-assistée dans la chirurgie des masses résiduelles après chimiothérapie : résultats oncologiques et fonctionnels
16. Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study
17. Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey
18. Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
19. VOTRAGE study pazopanib in a population of “frail” elderly patients after geriatric assessment: A phase I study with geriatric criteria
20. Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up
21. Apport d’une plateforme nationale de recherche clinique dédiée aux personnes âgées avec un cancer (PACAN : personnes âgées et cancer)
22. L’échappement thérapeutique des mélanomes traités par inhibiteur BRAF + MEK est préférentiellement intracrânien et agressif. Une cohorte de 52 patients
23. Feasibility and safety of lateral approach with single-docking robotic post chemotherapy modified retroperitoneal lymph node dissection in germ cell tumor
24. Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
25. Comment prendre en compte l’hétérogénéité dans le schéma des essais cliniques de phase II en oncogériatrie ?
26. DIALOG task force for definition of a geriatric minimum data set for clinical oncology research
27. Réactions lichénoïdes orales induites par les anticorps anti-PD1/PD-L1
28. How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial
29. Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
30. PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
31. Critères de jugement principaux dans les essais cliniques en oncogériatrie
32. Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
33. Premier cas de pustulose exanthématique aiguë généralisée survenant sous enzalutamide
34. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project
35. 2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer
36. Piloleiomyome cutané : un diagnostic dermatologique qui n’est pas anecdotique !
37. Is docetaxel-prednisone (DP) feasible in frail elderly (75+) patient with castration-resistant metastatic prostate cancer (CRMPC)? A prospective randomized study after geriatric assessment from gerico and getug unicancer groups
38. Standardization of the geriatric assessment within the Midi-Pyrenees Unite de Coordination in Oncogeriatrie
39. Trial on progress: VOTRAGE study Phase I study with geriatric criteria of Pazopanib in a population of frail elderly patients after geriatric assessment
40. Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)
41. Troubles de l’humeur et cognitifs et suppression androgénique
42. Influence of age on the pharmacokinetics of i.v. vinflunine: Results of a phase I trial in elderly cancer patients
43. 7016 POSTER Second Line Chemotherapy After Docetaxel Among Symptomatic Castration-Resistant Prostate Cancer (CPRC) Patients – GETUG-P02 Randomized Phase II Trial
44. Radiothérapie externe ou surveillance des séminomes testiculaires de stade 1 : comparaison des doses d’irradiation délivrées au testicule restant
45. Unité Pilote de Coordination en Oncogériatrie (UPCOG) Midi-Pyrénées: 1 year results elderly cancer patients, where do they come from?
46. P.3 Retrospective and comparative study of geriatric characteristics of Alzheimer disease (AD) patients with and without cancer (C)
47. Antithrombin III: structural and functional aspects
48. Crystallization and preliminary crystallographic data for bovine antithrombin III
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.